Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

(2020) Luca Cantini et al.   Frontiers in Oncology

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma

(2019) Yi-Hung Carol Tan et al.   Oncogenesis

STAT3, stem cells, cancer stem cells and p63

(2018) Michaela Galoczova et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

STAT3: a multifaceted oncoprotein

(2018) Aleks C. Guanizo et al.   GROWTH FACTORS

Viral manipulation of STAT3: Evade, exploit, and injure

(2018) Armando Andres Roca Suarez et al.   PLoS Pathogens

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion

(2018) Ramona Schulz-Heddergott et al.   CANCER CELL

ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy

(2018) Oliviero Marinelli et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade

(2018) Amir R. Aref et al.   LAB ON A CHIP

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

(2018) Julija Hmeljak et al.   Cancer Discovery

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

(2017) Russell W. Jenkins et al.   Cancer Discovery

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

(2016) M. Xiang et al.   BLOOD

JAK-STAT signaling in cancer: From cytokines to non-coding genome

(2016) Jan Pencik et al.   CYTOKINE

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

(2016) Raphael Bueno et al.   NATURE GENETICS

A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations

(2015) Claudia Canino et al.   Oncotarget

Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival

(2014) S. Dabir et al.   CLINICAL CANCER RESEARCH

CD90 Is a Diagnostic Marker to Differentiate Between Malignant Pleural Mesothelioma and Lung Carcinoma With Immunohistochemistry

(2013) Kiyoko Kawamura et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Activation of the NF-κB Pathway by the STAT3 Inhibitor JSI-124 in Human Glioblastoma Cells

(2013) Braden C. McFarland et al.   MOLECULAR CANCER RESEARCH

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

(2011) Ayumi Takakura et al.   HUMAN MOLECULAR GENETICS

Four-Gene Expression Ratio Test for Survival in Patients Undergoing Surgery for Mesothelioma

(2009) G. J. Gordon et al.   JNCI-Journal of the National Cancer Institute

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

(2008) E. A. Nelson et al.   BLOOD